Susquehanna International Group’s Dermata Therapeutics Warrant DRMAW Stock Holding History

Susquehanna International Group’s Portfolio DRMAW Stock Details DRMAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,671	Closed	-$253	–	13357
2025 Q4	$253	Buy	12,671 +2,495	+25%	+$54	﹤0.01%	12174
2025 Q3	$225	Sell	10,176 -547	-5%	-$11	﹤0.01%	12226
2025 Q2	$190	Buy	+10,723	New	+$198	﹤0.01%	12536

Other funds holding DRMAW

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Susquehanna International Group's DRMAW Position: Q1 2026 in Review

Susquehanna International Group sold out of Dermata Therapeutics Warrant (DRMAW) in Q1 2026, closing a stake of 12,671 shares — an estimated $253 sold.

Susquehanna International Group first reported a position in DRMAW in Q2 2025 and held it in 3 quarters. The position peaked at $253 in Q4 2025. 2 funds tracked by Wall St. Rank hold DRMAW as of Q1 2026.

Susquehanna International Group reported no remaining Dermata Therapeutics Warrant position as of Q1 2026 after selling out during the quarter.
Susquehanna International Group sold 12,671 Dermata Therapeutics Warrant shares in Q1 2026, an estimated $253.
Susquehanna International Group first reported a position in Dermata Therapeutics Warrant in Q2 2025 and held it in 3 quarters.
Susquehanna International Group's Dermata Therapeutics Warrant position peaked at $253 in Q4 2025.
2 funds tracked by Wall St. Rank held Dermata Therapeutics Warrant as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.